Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof

A levofloxacin and solvate technology, which is applied to medical preparations containing active ingredients, anti-infective drugs, anti-inflammatory agents, etc., can solve the problems of drug-resistant bacteria without enlightenment, and achieve the effect of inhibiting drug resistance

Inactive Publication Date: 2012-11-07
SANTEN PHARMA CO LTD +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Patent Document 1 is an invention that improves the antiseptic effect of the eye drops by blending polyhydric alcohols in the levofloxacin eye drops. There is no inspiration in the reports on how to cure eye infections within a short period of time and whether it can prevent the emergence of drug-resistant bacteria

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
  • Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
  • Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0069] [Clinical Trials]

[0070] The clinical test shown below was carried out, for the 1.5% (w / v) levofloxacin eye drops of the current dosage 3 times a day and the 0.5% (w / v) levofloxacin eye drops of the previous usage 3 times a day The effect (efficacy and safety) of the liquid group on bacterial conjunctivitis was studied comparatively.

[0071] (Preparation method of eye drops)

[0072] 1.5% (w / v) levofloxacin eye drops and 0.5% (w / v) levofloxacin eye drops are made by dissolving levofloxacin 1 / 2 hydrate in water, adding isotonic agent (glycerin) and pH regulator, and using Prepared according to general techniques (pH: 6.1-6.9).

[0073] (test procedure)

[0074] According to the dosage of 1 drop each time and 3 times a day, 1.5% (w / v) levofloxacin eye drops or 0.5% (w / v) levofloxacin eye drops are used for patients with bacterial conjunctivitis. Use 14 days. Taking the start date of eye instillation, the 3rd day, 7th day and 14th day of eye instillation as the ref...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are a method and dosage of eye drops containing 1.5% (w / v) of levofloxacin, characterized in that, when the eye drops are dropped into the eyes thrice a day, bacterial conjunctivitis can be healed within a short period of time, compared with the conventional case where 0.5% (w / v) eye drops are used thrice a day, without increasing the incidence of side effects. Healing of an eye infection within a short period of time contributes to shortening of the exposure time of a pathogenic bacterium causing the eye infection to levofloxacin. As a result, it is expected that, when used in the aforesaid method and dosage, the levofloxacin-containing eye drops inhibit the appearance of a resistant strain which is caused by the prolonged usage of levofloxacin-containing eye drops in the conventional method or dosage. Moreover, it is confirmed that, when used in the aforesaid method and dosage, the levofloxacin-containing eye drops directly inhibit the appearance of resistance, which is caused by the short-term usage of levofloxacin-containing eye drops in the conventional method or dosage, in pathogenic bacteria causative of eye infections such as Staphylococcus aureus.

Description

technical field [0001] The present invention relates to an eye drop, which is characterized in that it is an eye drop for the treatment of eye infections containing levofloxacin or its salts or their solvates at a concentration of 1.5% (w / v) as an active ingredient. Use 1 drop in each eye, 3 times a day. The present invention relates to a method for treating ocular infections using such levofloxacin or a salt thereof, or a solvate thereof. The present invention relates to levofloxacin or a salt thereof, or a solvate thereof for use in the treatment of the above-mentioned ocular infection. Furthermore, the present invention also relates to the use of the above-mentioned levofloxacin or its salt, or their solvate for producing the above-mentioned therapeutic agent for ocular infection. Background technique [0002] Levofloxacin is a new quinolone antibiotic that exhibits antibacterial activity by inhibiting DNA gyrase and topoisomerase IV, and is widely used. In my country,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5383A61P27/02A61P31/04
CPCA61K9/0048A61K31/5383A61P27/02A61P29/00A61P31/00A61P31/02A61P31/04A61K9/08A61K31/496A61K31/536
Inventor 长野敬阪中浩二中村雅胤河津刚一伊吹肇坂本佳代子
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap